Você procurou por: nefrotoksicitet (Dinamarquês - Inglês)

nefrotoksicitet
nephrotoxicity

nefrotoksicitet/neurotoksicitet
nephrotoxicity/neurotoxicity

forebyggelse af nefrotoksicitet
prevention of nephrotoxicity

bundet med nefrotoksicitet.
associated with nephrotoxicity.

nefrotoksicitet af nsaid’ er hos dehydrerede patienter.
nephrotoxicity of nsaids in dehydrated patients.

andre faktorer der kan forhøje risikoen for nefrotoksicitet
other factors that may increase the risk of nephrotoxicity

yderligere kan der forekomme synergistisk/additiv nefrotoksicitet.
in addition, synergistic/additive nephrotoxic effects can occur.

nefrotoksicitet inklusiv interstitiel nefritis og nefrotisk syndrom og
the following rare serious undesirable effects have been reported in association with the use of nsaids and cannot be ruled out for lumiracoxib: nephrotoxicity including interstitial nephritis and nephrotic syndrome and renal failure; hepatotoxicity including hepatic failure and jaundice; cutaneo- mucosal adverse effects and severe skin reactions.

nefrotoksicitet er blevet forbundet med behandling med parenteralt aminoglycosid.
nephrotoxicity has been associated with parenteral aminoglycoside therapy.

forhøjede ciclosporin-koncentrationer har været forbundet med nefrotoksicitet.
increased ciclosporin levels have been associated with nephrotoxicity.

øge risikoen for nefrotoksicitet og ototoksicitet (se pkt.4. 4) .
administration may increase the risk of nephrotoxicity and ototoxicity (see section 4.4) .

derudover er det fundet, at ataluren øgede intravenøse aminoglykosiders nefrotoksicitet.
in addition, ataluren was found to increase nephrotoxicity of intravenous aminoglycosides.

proteinuri synes at være en tidlig og følsom indikator for cidofovirinduceret nefrotoksicitet.
proteinuria appears to be an early and sensitive indicator of cidofovir-induced nephrotoxicity.

Øget nefrotoksicitet er set ved administrering af amfotericin b eller ibuprofen sammen med tacrolimus.
enhanced nephrotoxicity has been observed following the administration of amphotericin b and ibuprofen in conjunction with tacrolimus.

Øget nefrotoksicitet er set ved samtidig administrering af amphotericin b eller ibuprofen sammen med tacrolimus.
enhanced nephrotoxicity has been observed following the administration of amphotericin b and ibuprofen in conjunction with tacrolimus.

nefrotoksicitet inkluderende interstitiel nefritis og nefrotisk syndrom; hepatotoksicitet inkluderende leversvigt, icterus og pancreatitis.
the following serious undesirable effects have been reported in association with the use of nsaids and cannot be ruled out for etoricoxib: nephrotoxicity including interstitial nephritis and nephrotic syndrome; hepatotoxicity including hepatic failure, jaundice and pancreatitis.

i kliniske effektundersøgelser rapporteredes tilfælde af stigning i ciclosporinniveauer med alvorlige bivirkninger til følge, inklusive nefrotoksicitet samt et fatalt tilfælde af leukoencephalopati.
cases of elevated ciclosporin levels resulting in serious adverse events, including nephrotoxicity and one fatal case of leukoencephalopathy, were reported in clinical efficacy studies.

da den mekanisme, hvormed ataluren øger intravenøse aminoglykosiders nefrotoksicitet ikke er kendt, frarådes samtidig brug af andre nefrotoksiske lægemidler med ataluren.
since the mechanism by which ataluren increases nephrotoxicity of intravenous aminoglycosides is not known, concomitant use of other nephrotoxic medicinal products with ataluren is not recommended.

ved studier med gentagne doser hos mus, rotter og hunde var de vigtigste fund myelotoksicitet, nefrotoksicitet (bortset fra hunde) og testikelbeskadigelse.
in repeated-dose studies in mice, rats, and dogs, the main findings were myelotoxicity, nephrotoxicity (except dogs), and testicular damage.

hvis oto- eller nefrotoksicitet opstår hos en patient, som modtager tobi podhaler, skal tobramycin seponeres, indtil serumkoncentrationen er faldet til under 2 µg/ml.
if oto- or nephrotoxicity occurs in a patient receiving tobi podhaler, tobramycin therapy should be discontinued until serum concentration falls below 2 µg/ml.